Abstract
Adoptive cell therapy using cytotoxic CD8+ T lymphocytes (CTL) has shown promising results in recent clinical trials for cancer patients. Although significant advances have been achieved in this field, there are still many issues that need to be addressed before wide application of adoptive cellular immunotherapy as an adjuvant or mainstream therapy for various cancers. Difficulties related to the ex vivo generation of large number of effective antigen-specific CTLs, their in vivo tracking and short term survival following adoptive transfer are among the barriers decelerating the clinical use of this approach. In this review, we focus on recent developments in adoptive cell therapy using CD8 T cells and discuss the hurdles that need to be overcome. In addition, current status of adoptive cell transfer using other T cell populations for cancer immunotherapy that may circumvent some of the problems related to current protocols of using CTL is also discussed.
Keywords: Adoptive Cell Transfer, Chronic Myeloid Leukemia, Tumor Infiltrating Lymphocytes, Hematopoietic Stem Cell Transplantation, Peripheral Blood
Current Cancer Therapy Reviews
Title: Recent Advances in T Cell Adoptive Immunotherapy of Cancer
Volume: 4 Issue: 1
Author(s): Li Zhang and Pouneh Dokouhaki
Affiliation:
Keywords: Adoptive Cell Transfer, Chronic Myeloid Leukemia, Tumor Infiltrating Lymphocytes, Hematopoietic Stem Cell Transplantation, Peripheral Blood
Abstract: Adoptive cell therapy using cytotoxic CD8+ T lymphocytes (CTL) has shown promising results in recent clinical trials for cancer patients. Although significant advances have been achieved in this field, there are still many issues that need to be addressed before wide application of adoptive cellular immunotherapy as an adjuvant or mainstream therapy for various cancers. Difficulties related to the ex vivo generation of large number of effective antigen-specific CTLs, their in vivo tracking and short term survival following adoptive transfer are among the barriers decelerating the clinical use of this approach. In this review, we focus on recent developments in adoptive cell therapy using CD8 T cells and discuss the hurdles that need to be overcome. In addition, current status of adoptive cell transfer using other T cell populations for cancer immunotherapy that may circumvent some of the problems related to current protocols of using CTL is also discussed.
Export Options
About this article
Cite this article as:
Zhang Li and Dokouhaki Pouneh, Recent Advances in T Cell Adoptive Immunotherapy of Cancer, Current Cancer Therapy Reviews 2008; 4 (1) . https://dx.doi.org/10.2174/157339408783565475
DOI https://dx.doi.org/10.2174/157339408783565475 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Advances in Hyaluronic Acid-Based Drug Delivery Systems
Current Drug Targets Recent Advances in the Development of MMPIs and APNIs Based on the Pyrrolidine Platforms
Mini-Reviews in Medicinal Chemistry Heavy Metals and Epigenetic Alterations in Brain Tumors
Current Genomics Nanoemulsions for Skin Targeting: Present Status and Future Prospects
Drug Delivery Letters Systemic Treatment of Advanced Biliary Tract Carcinoma: Emerging Roles of Targeted Therapy and Molecular Profiling
Clinical Cancer Drugs The Complexity of DEK Signaling in Cancer Progression
Current Cancer Drug Targets Potassium Channels in Peripheral Pain Pathways: Expression, Function and Therapeutic Potential
Current Neuropharmacology Gemcitabine: A Critical Nucleoside for Cancer Therapy
Current Medicinal Chemistry Pharmacotherapy in Systemic Lupus Erythematosus
Current Rheumatology Reviews Benefits and Challenges of Antivirulence Antimicrobials at the Dawn of the Post-Antibiotic Era
Drug Delivery Letters Emerging Role of Circular RNAs in Kidney Diseases in Nephrology
Current Drug Targets Anti-Angiogenic Peptides for Cancer Therapeutics
Current Pharmaceutical Biotechnology Neuronal Acetylcholine Nicotinic Receptors as New Targets for Lung Cancer Treatment
Current Pharmaceutical Design New Approaches With Natural Product Drugs for Overcoming Multidrug Resistance in Cancer
Current Pharmaceutical Design Tumour Cytochrome P450 and Drug Activation
Current Pharmaceutical Design Meet Our Editorial Board Member
Current Drug Therapy Ligands and Therapeutic Perspectives of Adenosine A2A Receptors
Current Pharmaceutical Design Inflammatory and Non-Inflammatory Roles for Toll-Like Receptors in Gastrointestinal Cancer
Current Pharmaceutical Design Evaluation of Tricine and EDDA as Co-ligands for <sup>99m</sup>Tc-Labeled HYNIC-MSH Analogs for Melanoma Imaging
Anti-Cancer Agents in Medicinal Chemistry Pediatric Immune Dysfunction and Health Risks Following Early-Life Immune Insult
Current Pediatric Reviews